Literature DB >> 2829357

A newly defined property of somatotropin: priming of macrophages for production of superoxide anion.

C K Edwards1, S M Ghiasuddin, J M Schepper, L M Yunger, K W Kelley.   

Abstract

Macrophages can be activated to produce reactive oxygen intermediates, such as superoxide anion (O2-), which are responsible for intracellular killing of pathogenic microbes. Treatment with either native or recombinant somatotropin augmented the production of O2- by both peripheral blood-derived and alveolar macrophages stimulated with opsonized zymosan in vitro. This effect was abolished by prior treatment with an antibody specific for somatotropin. When either native or recombinant porcine somatotropin or native rat somatotropin was administered to hypophysectomized rats in vivo, activation of peritoneal macrophages, as measured by release of O2- in response to opsonized zymosan, was equivalent to that of macrophages from rats primed with the macrophage-activating factor interferon-gamma. Priming of macrophages in vivo was observed at physiologically relevant doses of somatotropin that caused a 10 to 40 percent increase in growth rate. Priming of mononuclear phagocytes for augmented production of reactive oxygen metabolites is a newly defined property of somatotropin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2829357     DOI: 10.1126/science.2829357

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  21 in total

1.  Characterization of the priming effect by pituitary canine growth hormone on canine polymorphonuclear neutrophil granulocyte function.

Authors:  T K Petersen; C W Smith; A L Jensen
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Chronic stress down-regulates growth hormone gene expression in peripheral blood mononuclear cells of older adults.

Authors:  W B Malarkey; H Wu; J T Cacioppo; K L Malarkey; K M Poehlmann; R Glaser; J K Kiecolt-Glaser
Journal:  Endocrine       Date:  1996-08       Impact factor: 3.633

3.  The interferon family stimulates the secretions of prolactin and interleukin-6 by the pituitary gland in vitro.

Authors:  M Yamaguchi; K Koike; N Matsuzaki; Y Yoshimoto; T Taniguchi; A Miyake; O Tanizawa
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

4.  Rational design of receptor-specific variants of human growth hormone.

Authors:  B C Cunningham; J A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 5.  Diabetic microangiopathy: IGFBP control endothelial cell growth by a common mechanism in spite of their species specificity and tissue peculiarity.

Authors:  S Giannini; B Cresci; C Manuelli; L Pala; C M Rotella
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

6.  Growth hormone activation of human monocytes for superoxide production but not tumor necrosis factor production, cell adherence, or action against Mycobacterium tuberculosis.

Authors:  J Warwick-Davies; D B Lowrie; P J Cole
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

7.  Causes of titanium release from plate and screws implanted in rabbits.

Authors:  Y Mu; T Kobayashi; K Tsuji; M Sumita; T Hanawa
Journal:  J Mater Sci Mater Med       Date:  2002-06       Impact factor: 3.896

8.  The macrophage-activating properties of growth hormone.

Authors:  C K Edwards; S Arkins; L M Yunger; A Blum; R Dantzer; K W Kelley
Journal:  Cell Mol Neurobiol       Date:  1992-10       Impact factor: 5.046

9.  The pituitary gland is required for protection against lethal effects of Salmonella typhimurium.

Authors:  C K Edwards; L M Yunger; R M Lorence; R Dantzer; K W Kelley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

10.  Reduction in superoxide anion secretion and bactericidal activity of neutrophils from aged rats: reversal by the combination of gamma interferon and growth hormone.

Authors:  Y K Fu; S Arkins; Y M Li; R Dantzer; K W Kelley
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.